Proceeds enable expansion of state-of-the art facility for producing breakthrough low-dose prebiotic organic PreneXOS
PRENEXUS HEALTH CLOSES ON SERIES B FINANCING
Previous
Previous
NEXXT LEVEL BRANDS PODCAST – HOW A VC FIRM LOOKS AT EMERGING BRANDS
Next
Next